DNAJC5 and malaria: Phase 2 clinical trials of an RTS, S/AS01 vaccine, a virus-like particle (VLP) consisting of a fragment (central repeat and C-terminal regions) of the CSP fused to a Hepatitis B Virus Surface Antigen (HBVsAg) (developed by GlaxoSmithKline), provided evidence for a high level of anti-CSP antibody response that correlated with reduced clinical malaria episodes.